---
title: "Invivyd 公司（IVVD）討論了 REVOLUTION 臨牀項目的進展以及麻疹單克隆抗體候選藥物的推進情況"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/282283900.md"
description: "Invivyd, Inc. (IVVD) 發佈了一份幻燈片，討論其 REVOLUTION 臨牀項目的進展。公司還強調了其麻疹單克隆抗體候選藥物的進展。這些信息以幻燈片的形式呈現給投資者"
datetime: "2026-04-10T03:40:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282283900.md)
  - [en](https://longbridge.com/en/news/282283900.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282283900.md)
---

# Invivyd 公司（IVVD）討論了 REVOLUTION 臨牀項目的進展以及麻疹單克隆抗體候選藥物的推進情況

Invivyd, Inc. (IVVD) has released a slide deck discussing the progress of its REVOLUTION Clinical Program. The company also highlighted the advancement of its measles monoclonal antibody candidate. This information is presented in a slideshow format for investors.

### 相關股票

- [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [IXJ.US](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [IVVD.US](https://longbridge.com/zh-HK/quote/IVVD.US.md)
- [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md)

## 相關資訊與研究

- [鉅亨速報 - Factset 最新調查：Roivant Sciences LtdROIV-US 的目標價調升至 38 元，幅度約 8.57%](https://longbridge.com/zh-HK/news/287126179.md)
- [復宏漢霖：注射用 HLX43 用於治療晚期非小細胞肺癌的國際多中心 2 期臨牀研究完成首例患者給藥](https://longbridge.com/zh-HK/news/287195179.md)
- [華爾街看好健康保險板塊，分析師上調多家公司評級](https://longbridge.com/zh-HK/news/287081375.md)
- [川普投資組合神操作？Medicare 政策翻盤前 精準大買聯合健康](https://longbridge.com/zh-HK/news/287039034.md)
- [瑞銀上調爵士製藥評級：核心業務韌性強勁，新藥 Ziihera 成增長引擎](https://longbridge.com/zh-HK/news/286920691.md)